Effect of levamisole on cell-mediated immune responses in patients with nasopharyngeal carcinoma.
CMI functions, as monitored by responses in the Mantoux and PHA tests, can be augmented by a short oral course of levamisole. The augmentation is dosage dependent and, in some patients, of long duration.
D002277:Carcinoma / Q000276:immunology* / Q000532:radiotherapy; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007978:Levamisole / Q000008:administration & dosage / Q000494:pharmacology*; D008137:Longitudinal Studies; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000276:immunology; D009303:Nasopharyngeal Neoplasms / Q000276:immunology* / Q000532:radiotherapy; D010835:Phytohemagglutinins / Q000494:pharmacology; D013268:Stimulation, Chemical; D014374:Tuberculin Test
D010835:Phytohemagglutinins; D007978:Levamisole